PDZK1 inhibits MRP2-mediated oxaliplatin chemosensitivity in hepatocellular carcinoma

Chunjuan Zhao(Capital Medical University), Yi Chen(Fujian Medical University), Chao Ren(Shanxi Medical University), Yanbo Ma(Shanxi Medical University), Duiping Feng(Shanxi Medical University), Jinyu Li(Central South University)
Scientific Reports
April 18, 2025
10.1038/s41598-025-98085-x
Cited by 1

Related Papers

The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
|Frontiers in Oncology|2021|87
Loss of PDZK1 expression activates PI3K/AKT signaling via PTEN phosphorylation in gastric cancer
|Cancer Letters|2019|72
E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer
|Molecular Cancer|2022|70
Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival
|European Radiology|2020|51
PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation
|Oncogene|2017|49